Current therapy and new drugs: a road to personalized treatment of myelodysplastic syndromes-Reference-Cited by-同舟云学术

Current therapy and new drugs: a road to personalized treatment of myelodysplastic syndromes

Published:2017-12-27 Issue:1 Volume:3 Page:23-31
ISSN:2380-8993
Container-title:Expert Review of Precision Medicine and Drug Development
language:en
Short-container-title:Expert Review of Precision Medicine and Drug Development

Author:

Parisi Sarah¹,Ratti Stefano²,Mongiorgi Sara²,Suh Pann-Ghill³,Manzoli Lucia²,McCubrey James A.⁴,Cocco Lucio²,Follo Matilde Y.²,Finelli Carlo¹

Affiliation:

1. Department of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology “L. e A. Seràgnoli”, S. Orsola-Malpighi Hospital, Bologna, Italy

2. Cellular Signalling Laboratory, Institute of Human Anatomy DIBINEM, University of Bologna, Bologna, Italy

3. School of Life Sciences, UNIST, Ulsan, Republic of Korea

4. Department of Microbiology and Immunology, Brody School of Medicine, East Carolina University, Greenville, NC, USA

Funder

Italian MIUR-PRIN

Intesa S. Paolo

Publisher

Informa UK Limited

Subject

Drug Discovery,Pharmacology,Genetics,Molecular Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/23808993.2018.1419820

Reference100 articles.

1. First-line Therapeutic Strategies for Myelodysplastic Syndromes

2. Myelodysplastic syndromes

3. Idiopathic cytopenia of undetermined significance (ICUS) versus low risk MDS: The diagnostic interface

4. Changes in the Updated 2016: WHO Classification of the Myelodysplastic Syndromes and Related Myeloid Neoplasms

5. The 2016 revised World Health Organization definition of ‘myelodysplastic syndrome with isolated del(5q)’; prognostic implications of single versus double cytogenetic abnormalities

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nuclear Inositides and Inositide-Dependent Signaling Pathways in Myelodysplastic Syndromes;Cells;2020-03-12